ABBV vs DERM

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Journey Medical (DERM) maintains its high-risk, high-reward profile, primarily driven by the upcoming PDUFA decision for DFD-29 in Q3 2026. The Q1 2026 earnings report showed positive signs with a revenue beat ($15.96M vs. $15.47M consensus), 21% YoY growth, narrowing losses (EPS $(0.08)$ vs $(0.18)$ YoY), and positive Adjusted EBITDA of $0.62M. Cash and equivalents also increased to $27.22M, prov...